Amgen beats on revenue and EPS
Amgen delivered a clean quarter with double-digit revenue growth and strong cash generation, though the stock's sharp rally likely reflects relief that guidance was maintained despite biosimilar headwinds on key franchises.
Sources: https://www.sec.gov/Archives/edgar/data/318154/000031815426000124/amgn-20260804.htm, https://www.sec.gov/Archives/edgar/data/3
Previous verdicts for AMGN
- AI Search: Amgen Rallies Sharply as Q3 Beat and Raised Guidance Reverse the Slide — 2026-11-04
- Beat, stock falls — 2026-11-03
- AI Search: Amgen Edges Up Slightly as Technical Setup Builds — 2026-11-02
- AI Search: Amgen Rallies Sharply as Analyst Reaffirmation and Rare Disease News Land — 2026-10-29
- Upgrade sparks violent rally — 2026-05-08
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works